Core Viewpoint - The company, Lingyi Zhi Zao (002600.SZ), is planning to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international strategy and expand overseas business operations [1] Group 1: International Strategy - The company aims to promote its internationalization strategy and strengthen its overseas business layout [1] - The initiative is expected to broaden the company's merger and acquisition as well as financing channels [1] Group 2: Competitive Positioning - The issuance of H-shares is intended to increase the company's international visibility and overall competitiveness [1] - The company assures that this H-share issuance will not lead to any changes in the controlling shareholder or actual controller [1]

Core Viewpoint - The red-chip structure, due to its flexibility and compliance advantages, has become an excellent choice for companies seeking overseas financing and listing amid globalization. However, the process is complex and requires careful navigation of regulatory requirements to avoid potential pitfalls [1]. Key Steps: "Six Steps" from Structure Design to Compliance Loop - The core of the red-chip structure is "overseas holding + domestic operation," utilizing offshore SPVs (such as BVI or Cayman Islands) to hold equity in domestic WFOEs, ultimately leading to overseas listings [3]. - Three key elements must be clarified in advance: equity structure, investment path, and return plan [6]. - The overseas SPV serves as the "core hub," typically registered in BVI (tax transparency, strong confidentiality) or Cayman (high international recognition, ease of listing) [5]. Coordination Principles: "Four Golden Principles" - The 37th document registration is applicable to Chinese individuals (founders, shareholders, employees) to address compliance issues related to overseas holdings [10]. - ODI registration is required for domestic corporate entities to ensure compliance for overseas direct investments [10]. - It is advisable to synchronize the processing of 37th document registration and ODI registration materials to avoid delays in overall progress [10]. Practical Recommendations: Professional Guidance to Avoid Compliance Pitfalls - The establishment of a red-chip structure and compliance with cross-border investment regulations involves multiple areas, including foreign exchange management, business approvals, and tax planning [20]. - Companies are encouraged to consult professional lawyers or advisory firms to develop compliance plans tailored to their specific situations, potentially saving significant costs and time [20].

Core Viewpoint - Guanghetong (300638.SZ) is in the process of applying for the issuance of overseas listed foreign shares (H-shares) and plans to list on the main board of the Hong Kong Stock Exchange [1] Group 1 - The listing hearing by the Hong Kong Stock Exchange Listing Committee is scheduled for September 25, 2025, to review the company's application for issuance and listing [1] - The sponsor of the company's issuance and listing received a letter from the Hong Kong Stock Exchange on September 26, 2025, indicating that the Listing Committee has reviewed the company's application [1] - The letter from the Hong Kong Stock Exchange does not constitute approval for the listing and does not guarantee that approval will be granted [1]

Group 1 - The company has submitted an application for the issuance of overseas listed shares (H-shares) and listing on the Hong Kong Stock Exchange on September 25, 2025 [1] - The application materials are prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange, and may be updated and revised [1] - The subscription for this issuance is limited to qualified overseas investors and domestic qualified investors who are authorized to conduct overseas securities investments under Chinese laws and regulations [1] Group 2 - The company must meet several conditions for the issuance and listing, including obtaining approvals from the China Securities Regulatory Commission, the Hong Kong Securities and Futures Commission, the Hong Kong Stock Exchange, and other relevant regulatory bodies [2] - The implementation of the issuance is subject to market conditions and other factors, indicating uncertainty [2] - The company will fulfill its information disclosure obligations in a timely manner based on the progress of relevant matters [2]

Core Viewpoint - Hailiang Co., Ltd. plans to issue H-shares and list on the Hong Kong Stock Exchange to enhance its international image and competitiveness, as well as to strengthen connections with overseas capital markets [1] Group 1 - The company is advancing its globalization strategy as part of its overall development plan [1] - The company is currently in discussions with relevant intermediaries regarding the H-share issuance and listing [1] - Specific details of the H-share issuance and listing have not yet been finalized [1]

智通财经APP讯，科大智能(300222.SZ)公告，公司拟筹划境外发行股份(H股)并申请在中国香港联交所 主板挂牌上市。截至目前，公司正在计划与相关中介机构就本次发行H股并上市的相关工作进行商讨， 关于本次发行H股并上市的细节尚未确定。 ...

Group 1 - The company, Keda Intelligent (300222.SZ), plans to issue H-shares and apply for listing on the main board of the Hong Kong Stock Exchange [1] - Currently, the company is in discussions with relevant intermediaries regarding the issuance of H-shares and the listing process [1] - Details regarding the issuance of H-shares and the listing have not yet been finalized [1]

Core Viewpoint - The company, Wanxing Technology (300624.SZ), has submitted an application for the issuance of overseas listed shares (H-shares) and for listing on the main board of the Hong Kong Stock Exchange on September 25, 2025 [1] Group 1 - The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission and the Hong Kong Stock Exchange [1] - The submitted application documents are in draft form and may be updated and revised as necessary [1]

Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are seeking to list in Hong Kong [1] Group 1: Company Summaries - **Lemo**: Plans to issue up to 19,166,700 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Lemo is a machine massage service provider with over 48,000 service points and more than 535,000 massage machines deployed as of July 18, 2025. Revenue for 2022 to 2024 is projected at 330 million, 587 million, and 798 million CNY, with corresponding net profits of 6.48 million, 87.34 million, and 85.81 million CNY [3][5] - **Dipu**: Plans to issue up to 115,000,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Dipu focuses on providing AI solutions, including big data analysis and enterprise-level model applications, across various sectors. Revenue for 2022 to 2024 is projected at 100 million, 129 million, and 243 million CNY, with corresponding net losses of 655 million, 503 million, and 1.255 billion CNY [5][7] - **Red Star Cold Chain**: Plans to issue up to 26,752,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Red Star Cold Chain operates a platform for frozen food trading and storage services. Revenue for 2022 to 2024 is projected at 237 million, 202 million, and 234 million CNY, with corresponding net profits of 79 million, 75 million, and 83 million CNY [7][9] - **Sailis**: Plans to issue up to 331,477,235 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Sailis is a technology-driven automotive company focused on electric vehicles, having launched several models. Revenue for 2022 to 2024 is projected at 34.1 billion, 35.8 billion, and 145.1 billion CNY, with corresponding net losses of 5.2 billion, 4.2 billion, and a net profit of 4.7 billion CNY [9][11] - **Yiteng Pharmaceutical**: Plans to achieve a listing on the Hong Kong Stock Exchange through a merger with Genor Biopharma Holdings Limited, which will issue up to 1,883,972,094 ordinary shares. Yiteng focuses on the R&D, production, and commercialization of biopharmaceutical products across various therapeutic areas. Revenue for 2022 to 2024 is projected at 2.073 billion, 2.304 billion, and 2.546 billion CNY, with corresponding net profits of 306 million, 308 million, and 388 million CNY [11]

Core Points - Company has received a notification from the China Securities Regulatory Commission regarding the overseas issuance and listing, marking significant progress in its efforts to go public abroad [2] - The company plans to issue up to 331,477,235 overseas listed ordinary shares (H-shares) and list them on the Hong Kong Stock Exchange [2] - The company must report any major events to the China Securities Regulatory Commission during the overseas listing process and must also report the issuance and listing status within 15 working days after completion [2] Production and Sales Data - In August, the company's total automobile production reached 47,097 units, representing a year-on-year increase of 14.24% [2] - The cumulative total production for the year stands at 296,202 units, showing a year-on-year decrease of 9.21% [2] - The total automobile sales in August were 45,818 units, reflecting a year-on-year increase of 8.43% [2] - The cumulative total sales for the year are 292,364 units, indicating a year-on-year decline of 10% [2]